Global Human Micobiome

Human Micobiome Comprehensive Study by Type (Probiotics, Prebiotics, Foods, Medical Foods, Diagnostic Tests, Drugs, Others), Application (Therapeutics, Diagnostics, Others), Technology (Genomics, Proteomics, Metabolomics, Others), Disease (Infectious Diseases, Endocrine and Metabolic Disorders, Inflammatory Diseases, Cancer, Others) Players and Region - Global Market Outlook to 2030

Human Micobiome Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 21.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Human Micobiome
The human microbiome is the combination of all microbiota that exist in on or within human tissues and biofluids along with the corresponding anatomical sites in which they reside including saliva, mammary glands, skin, uterus, lung, and so on. The human microbiome plays a main role in modern healthcare, as it allows easy digestion of food, regulation of the immune system, and production of vitamins such as Vitamin K, Vitamin B, and Vitamin B12, which is necessary for blood coagulation. According to the Research for Disease Control and prevention in 2015, Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections in the U.S., moving over 500,000 people and reason about 29,000 deaths each year

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR21.6%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Human Micobiome market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

4D Pharma (United Kingdom), Yakult Honsha Co., Ltd (Japan), DuPont (United States), Rebiotix, Inc. (United States), Metabiomics Corporation (United States), Second Genome Inc (United States), AstraZeneca (United Kingdom), Merck & Co., Inc (United States), Synthetic Biologics, Inc. (United States), Seres Therapeutics (United States) and Microbiome Therapeutics LLC (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Vedanta BioSciences (United States), Seres Therapeutics (United States), Enterome Bioscience (France) and Seres Therapeutics (United States).

Segmentation Overview
AMA Research has segmented the market of Global Human Micobiome market by Type (Probiotics, Prebiotics, Foods, Medical Foods, Diagnostic Tests, Drugs and Others), Application (Therapeutics, Diagnostics and Others) and Region.



On the basis of geography, the market of Human Micobiome has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology , the sub-segment i.e. Genomics will boost the Human Micobiome market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease , the sub-segment i.e. Infectious Diseases will boost the Human Micobiome market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Therapeutic Applications Expected to Hold the Highest Share During Forecast Period

Market Growth Drivers:
Mounting prevalence of gastrointestinal disorder and cancer and Increasing Number of Cancer Cases

Challenges:
Stringent Government Regulations

Restraints:
Lack of Expertise and Detailed Research and Obstruction in Proving the Causal Link Between Disease and Dysbiosis

Opportunities:
The growing need for early detection and diagnostics of cancer is expected to boost demand and create the opportunities of growth for the human microbiome market.

Market Leaders and their expansionary development strategies
In March 2024, Danish microbiome profiling firm Clinical Microbiomics that it has acquired long-read microbial sequencing service company DNASense. The partnership with DNASense expands our portfolio of services and opens up new segments beyond human microbiome
In June 2023, UW Medicine launched the Microbial Interactions & Microbiome Center to investigate the diverse communities of microorganisms that inhabit nearly every environment, including parts of our bodies like the gut, mouth, and skin.


Key Target Audience
Human Microbiome Solution vendors, Original Equipment Manufacturers (OEMs), System integrators, Advisory firms, National regulatory authorities, Venture capitalists, Private equity groups, Investment houses and Equity research firms

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Probiotics
  • Prebiotics
  • Foods
  • Medical Foods
  • Diagnostic Tests
  • Drugs
  • Others
By Application
  • Therapeutics
  • Diagnostics
  • Others
By Technology
  • Genomics
  • Proteomics
  • Metabolomics
  • Others

By Disease
  • Infectious Diseases
  • Endocrine and Metabolic Disorders
  • Inflammatory Diseases
  • Cancer
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Mounting prevalence of gastrointestinal disorder and cancer
      • 3.2.2. Increasing Number of Cancer Cases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Therapeutic Applications Expected to Hold the Highest Share During Forecast Period
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Micobiome, by Type, Application, Technology , Disease and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Human Micobiome (Value)
      • 5.2.1. Global Human Micobiome by: Type (Value)
        • 5.2.1.1. Probiotics
        • 5.2.1.2. Prebiotics
        • 5.2.1.3. Foods
        • 5.2.1.4. Medical Foods
        • 5.2.1.5. Diagnostic Tests
        • 5.2.1.6. Drugs
        • 5.2.1.7. Others
      • 5.2.2. Global Human Micobiome by: Application (Value)
        • 5.2.2.1. Therapeutics
        • 5.2.2.2. Diagnostics
        • 5.2.2.3. Others
      • 5.2.3. Global Human Micobiome Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Human Micobiome (Volume)
      • 5.3.1. Global Human Micobiome by: Type (Volume)
        • 5.3.1.1. Probiotics
        • 5.3.1.2. Prebiotics
        • 5.3.1.3. Foods
        • 5.3.1.4. Medical Foods
        • 5.3.1.5. Diagnostic Tests
        • 5.3.1.6. Drugs
        • 5.3.1.7. Others
      • 5.3.2. Global Human Micobiome by: Application (Volume)
        • 5.3.2.1. Therapeutics
        • 5.3.2.2. Diagnostics
        • 5.3.2.3. Others
      • 5.3.3. Global Human Micobiome Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Human Micobiome (Price)
      • 5.4.1. Global Human Micobiome by: Type (Price)
  • 6. Human Micobiome: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. 4D Pharma (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Yakult Honsha Co., Ltd (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. DuPont (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Rebiotix, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Metabiomics Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Second Genome Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Synthetic Biologics, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Seres Therapeutics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Microbiome Therapeutics LLC (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Human Micobiome Sale, by Type, Application, Technology , Disease and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Human Micobiome (Value)
      • 7.2.1. Global Human Micobiome by: Type (Value)
        • 7.2.1.1. Probiotics
        • 7.2.1.2. Prebiotics
        • 7.2.1.3. Foods
        • 7.2.1.4. Medical Foods
        • 7.2.1.5. Diagnostic Tests
        • 7.2.1.6. Drugs
        • 7.2.1.7. Others
      • 7.2.2. Global Human Micobiome by: Application (Value)
        • 7.2.2.1. Therapeutics
        • 7.2.2.2. Diagnostics
        • 7.2.2.3. Others
      • 7.2.3. Global Human Micobiome Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Human Micobiome (Volume)
      • 7.3.1. Global Human Micobiome by: Type (Volume)
        • 7.3.1.1. Probiotics
        • 7.3.1.2. Prebiotics
        • 7.3.1.3. Foods
        • 7.3.1.4. Medical Foods
        • 7.3.1.5. Diagnostic Tests
        • 7.3.1.6. Drugs
        • 7.3.1.7. Others
      • 7.3.2. Global Human Micobiome by: Application (Volume)
        • 7.3.2.1. Therapeutics
        • 7.3.2.2. Diagnostics
        • 7.3.2.3. Others
      • 7.3.3. Global Human Micobiome Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Human Micobiome (Price)
      • 7.4.1. Global Human Micobiome by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Micobiome: by Type(USD Million)
  • Table 2. Human Micobiome Probiotics , by Region USD Million (2018-2023)
  • Table 3. Human Micobiome Prebiotics , by Region USD Million (2018-2023)
  • Table 4. Human Micobiome Foods , by Region USD Million (2018-2023)
  • Table 5. Human Micobiome Medical Foods , by Region USD Million (2018-2023)
  • Table 6. Human Micobiome Diagnostic Tests , by Region USD Million (2018-2023)
  • Table 7. Human Micobiome Drugs , by Region USD Million (2018-2023)
  • Table 8. Human Micobiome Others , by Region USD Million (2018-2023)
  • Table 9. Human Micobiome: by Application(USD Million)
  • Table 10. Human Micobiome Therapeutics , by Region USD Million (2018-2023)
  • Table 11. Human Micobiome Diagnostics , by Region USD Million (2018-2023)
  • Table 12. Human Micobiome Others , by Region USD Million (2018-2023)
  • Table 13. South America Human Micobiome, by Country USD Million (2018-2023)
  • Table 14. South America Human Micobiome, by Type USD Million (2018-2023)
  • Table 15. South America Human Micobiome, by Application USD Million (2018-2023)
  • Table 16. South America Human Micobiome, by Technology USD Million (2018-2023)
  • Table 17. South America Human Micobiome, by Disease USD Million (2018-2023)
  • Table 18. Brazil Human Micobiome, by Type USD Million (2018-2023)
  • Table 19. Brazil Human Micobiome, by Application USD Million (2018-2023)
  • Table 20. Brazil Human Micobiome, by Technology USD Million (2018-2023)
  • Table 21. Brazil Human Micobiome, by Disease USD Million (2018-2023)
  • Table 22. Argentina Human Micobiome, by Type USD Million (2018-2023)
  • Table 23. Argentina Human Micobiome, by Application USD Million (2018-2023)
  • Table 24. Argentina Human Micobiome, by Technology USD Million (2018-2023)
  • Table 25. Argentina Human Micobiome, by Disease USD Million (2018-2023)
  • Table 26. Rest of South America Human Micobiome, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Human Micobiome, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Human Micobiome, by Technology USD Million (2018-2023)
  • Table 29. Rest of South America Human Micobiome, by Disease USD Million (2018-2023)
  • Table 30. Asia Pacific Human Micobiome, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific Human Micobiome, by Type USD Million (2018-2023)
  • Table 32. Asia Pacific Human Micobiome, by Application USD Million (2018-2023)
  • Table 33. Asia Pacific Human Micobiome, by Technology USD Million (2018-2023)
  • Table 34. Asia Pacific Human Micobiome, by Disease USD Million (2018-2023)
  • Table 35. China Human Micobiome, by Type USD Million (2018-2023)
  • Table 36. China Human Micobiome, by Application USD Million (2018-2023)
  • Table 37. China Human Micobiome, by Technology USD Million (2018-2023)
  • Table 38. China Human Micobiome, by Disease USD Million (2018-2023)
  • Table 39. Japan Human Micobiome, by Type USD Million (2018-2023)
  • Table 40. Japan Human Micobiome, by Application USD Million (2018-2023)
  • Table 41. Japan Human Micobiome, by Technology USD Million (2018-2023)
  • Table 42. Japan Human Micobiome, by Disease USD Million (2018-2023)
  • Table 43. India Human Micobiome, by Type USD Million (2018-2023)
  • Table 44. India Human Micobiome, by Application USD Million (2018-2023)
  • Table 45. India Human Micobiome, by Technology USD Million (2018-2023)
  • Table 46. India Human Micobiome, by Disease USD Million (2018-2023)
  • Table 47. South Korea Human Micobiome, by Type USD Million (2018-2023)
  • Table 48. South Korea Human Micobiome, by Application USD Million (2018-2023)
  • Table 49. South Korea Human Micobiome, by Technology USD Million (2018-2023)
  • Table 50. South Korea Human Micobiome, by Disease USD Million (2018-2023)
  • Table 51. Taiwan Human Micobiome, by Type USD Million (2018-2023)
  • Table 52. Taiwan Human Micobiome, by Application USD Million (2018-2023)
  • Table 53. Taiwan Human Micobiome, by Technology USD Million (2018-2023)
  • Table 54. Taiwan Human Micobiome, by Disease USD Million (2018-2023)
  • Table 55. Australia Human Micobiome, by Type USD Million (2018-2023)
  • Table 56. Australia Human Micobiome, by Application USD Million (2018-2023)
  • Table 57. Australia Human Micobiome, by Technology USD Million (2018-2023)
  • Table 58. Australia Human Micobiome, by Disease USD Million (2018-2023)
  • Table 59. Rest of Asia-Pacific Human Micobiome, by Type USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Human Micobiome, by Application USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Human Micobiome, by Technology USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Human Micobiome, by Disease USD Million (2018-2023)
  • Table 63. Europe Human Micobiome, by Country USD Million (2018-2023)
  • Table 64. Europe Human Micobiome, by Type USD Million (2018-2023)
  • Table 65. Europe Human Micobiome, by Application USD Million (2018-2023)
  • Table 66. Europe Human Micobiome, by Technology USD Million (2018-2023)
  • Table 67. Europe Human Micobiome, by Disease USD Million (2018-2023)
  • Table 68. Germany Human Micobiome, by Type USD Million (2018-2023)
  • Table 69. Germany Human Micobiome, by Application USD Million (2018-2023)
  • Table 70. Germany Human Micobiome, by Technology USD Million (2018-2023)
  • Table 71. Germany Human Micobiome, by Disease USD Million (2018-2023)
  • Table 72. France Human Micobiome, by Type USD Million (2018-2023)
  • Table 73. France Human Micobiome, by Application USD Million (2018-2023)
  • Table 74. France Human Micobiome, by Technology USD Million (2018-2023)
  • Table 75. France Human Micobiome, by Disease USD Million (2018-2023)
  • Table 76. Italy Human Micobiome, by Type USD Million (2018-2023)
  • Table 77. Italy Human Micobiome, by Application USD Million (2018-2023)
  • Table 78. Italy Human Micobiome, by Technology USD Million (2018-2023)
  • Table 79. Italy Human Micobiome, by Disease USD Million (2018-2023)
  • Table 80. United Kingdom Human Micobiome, by Type USD Million (2018-2023)
  • Table 81. United Kingdom Human Micobiome, by Application USD Million (2018-2023)
  • Table 82. United Kingdom Human Micobiome, by Technology USD Million (2018-2023)
  • Table 83. United Kingdom Human Micobiome, by Disease USD Million (2018-2023)
  • Table 84. Netherlands Human Micobiome, by Type USD Million (2018-2023)
  • Table 85. Netherlands Human Micobiome, by Application USD Million (2018-2023)
  • Table 86. Netherlands Human Micobiome, by Technology USD Million (2018-2023)
  • Table 87. Netherlands Human Micobiome, by Disease USD Million (2018-2023)
  • Table 88. Rest of Europe Human Micobiome, by Type USD Million (2018-2023)
  • Table 89. Rest of Europe Human Micobiome, by Application USD Million (2018-2023)
  • Table 90. Rest of Europe Human Micobiome, by Technology USD Million (2018-2023)
  • Table 91. Rest of Europe Human Micobiome, by Disease USD Million (2018-2023)
  • Table 92. MEA Human Micobiome, by Country USD Million (2018-2023)
  • Table 93. MEA Human Micobiome, by Type USD Million (2018-2023)
  • Table 94. MEA Human Micobiome, by Application USD Million (2018-2023)
  • Table 95. MEA Human Micobiome, by Technology USD Million (2018-2023)
  • Table 96. MEA Human Micobiome, by Disease USD Million (2018-2023)
  • Table 97. Middle East Human Micobiome, by Type USD Million (2018-2023)
  • Table 98. Middle East Human Micobiome, by Application USD Million (2018-2023)
  • Table 99. Middle East Human Micobiome, by Technology USD Million (2018-2023)
  • Table 100. Middle East Human Micobiome, by Disease USD Million (2018-2023)
  • Table 101. Africa Human Micobiome, by Type USD Million (2018-2023)
  • Table 102. Africa Human Micobiome, by Application USD Million (2018-2023)
  • Table 103. Africa Human Micobiome, by Technology USD Million (2018-2023)
  • Table 104. Africa Human Micobiome, by Disease USD Million (2018-2023)
  • Table 105. North America Human Micobiome, by Country USD Million (2018-2023)
  • Table 106. North America Human Micobiome, by Type USD Million (2018-2023)
  • Table 107. North America Human Micobiome, by Application USD Million (2018-2023)
  • Table 108. North America Human Micobiome, by Technology USD Million (2018-2023)
  • Table 109. North America Human Micobiome, by Disease USD Million (2018-2023)
  • Table 110. United States Human Micobiome, by Type USD Million (2018-2023)
  • Table 111. United States Human Micobiome, by Application USD Million (2018-2023)
  • Table 112. United States Human Micobiome, by Technology USD Million (2018-2023)
  • Table 113. United States Human Micobiome, by Disease USD Million (2018-2023)
  • Table 114. Canada Human Micobiome, by Type USD Million (2018-2023)
  • Table 115. Canada Human Micobiome, by Application USD Million (2018-2023)
  • Table 116. Canada Human Micobiome, by Technology USD Million (2018-2023)
  • Table 117. Canada Human Micobiome, by Disease USD Million (2018-2023)
  • Table 118. Mexico Human Micobiome, by Type USD Million (2018-2023)
  • Table 119. Mexico Human Micobiome, by Application USD Million (2018-2023)
  • Table 120. Mexico Human Micobiome, by Technology USD Million (2018-2023)
  • Table 121. Mexico Human Micobiome, by Disease USD Million (2018-2023)
  • Table 122. Human Micobiome Sales: by Type(K Units)
  • Table 123. Human Micobiome Sales Probiotics , by Region K Units (2018-2023)
  • Table 124. Human Micobiome Sales Prebiotics , by Region K Units (2018-2023)
  • Table 125. Human Micobiome Sales Foods , by Region K Units (2018-2023)
  • Table 126. Human Micobiome Sales Medical Foods , by Region K Units (2018-2023)
  • Table 127. Human Micobiome Sales Diagnostic Tests , by Region K Units (2018-2023)
  • Table 128. Human Micobiome Sales Drugs , by Region K Units (2018-2023)
  • Table 129. Human Micobiome Sales Others , by Region K Units (2018-2023)
  • Table 130. Human Micobiome Sales: by Application(K Units)
  • Table 131. Human Micobiome Sales Therapeutics , by Region K Units (2018-2023)
  • Table 132. Human Micobiome Sales Diagnostics , by Region K Units (2018-2023)
  • Table 133. Human Micobiome Sales Others , by Region K Units (2018-2023)
  • Table 134. South America Human Micobiome Sales, by Country K Units (2018-2023)
  • Table 135. South America Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 136. South America Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 137. South America Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 138. South America Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 139. Brazil Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 140. Brazil Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 141. Brazil Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 142. Brazil Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 143. Argentina Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 144. Argentina Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 145. Argentina Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 146. Argentina Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 147. Rest of South America Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 148. Rest of South America Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 149. Rest of South America Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 150. Rest of South America Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 151. Asia Pacific Human Micobiome Sales, by Country K Units (2018-2023)
  • Table 152. Asia Pacific Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 153. Asia Pacific Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 154. Asia Pacific Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 155. Asia Pacific Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 156. China Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 157. China Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 158. China Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 159. China Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 160. Japan Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 161. Japan Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 162. Japan Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 163. Japan Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 164. India Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 165. India Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 166. India Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 167. India Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 168. South Korea Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 169. South Korea Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 170. South Korea Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 171. South Korea Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 172. Taiwan Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 173. Taiwan Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 174. Taiwan Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 175. Taiwan Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 176. Australia Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 177. Australia Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 178. Australia Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 179. Australia Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 180. Rest of Asia-Pacific Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 181. Rest of Asia-Pacific Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 182. Rest of Asia-Pacific Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 183. Rest of Asia-Pacific Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 184. Europe Human Micobiome Sales, by Country K Units (2018-2023)
  • Table 185. Europe Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 186. Europe Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 187. Europe Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 188. Europe Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 189. Germany Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 190. Germany Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 191. Germany Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 192. Germany Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 193. France Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 194. France Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 195. France Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 196. France Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 197. Italy Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 198. Italy Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 199. Italy Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 200. Italy Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 201. United Kingdom Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 202. United Kingdom Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 203. United Kingdom Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 204. United Kingdom Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 205. Netherlands Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 206. Netherlands Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 207. Netherlands Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 208. Netherlands Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 209. Rest of Europe Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 210. Rest of Europe Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 211. Rest of Europe Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 212. Rest of Europe Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 213. MEA Human Micobiome Sales, by Country K Units (2018-2023)
  • Table 214. MEA Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 215. MEA Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 216. MEA Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 217. MEA Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 218. Middle East Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 219. Middle East Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 220. Middle East Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 221. Middle East Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 222. Africa Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 223. Africa Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 224. Africa Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 225. Africa Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 226. North America Human Micobiome Sales, by Country K Units (2018-2023)
  • Table 227. North America Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 228. North America Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 229. North America Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 230. North America Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 231. United States Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 232. United States Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 233. United States Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 234. United States Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 235. Canada Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 236. Canada Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 237. Canada Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 238. Canada Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 239. Mexico Human Micobiome Sales, by Type K Units (2018-2023)
  • Table 240. Mexico Human Micobiome Sales, by Application K Units (2018-2023)
  • Table 241. Mexico Human Micobiome Sales, by Technology K Units (2018-2023)
  • Table 242. Mexico Human Micobiome Sales, by Disease K Units (2018-2023)
  • Table 243. Human Micobiome: by Type(USD/Units)
  • Table 244. Company Basic Information, Sales Area and Its Competitors
  • Table 245. Company Basic Information, Sales Area and Its Competitors
  • Table 246. Company Basic Information, Sales Area and Its Competitors
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Human Micobiome: by Type(USD Million)
  • Table 256. Human Micobiome Probiotics , by Region USD Million (2025-2030)
  • Table 257. Human Micobiome Prebiotics , by Region USD Million (2025-2030)
  • Table 258. Human Micobiome Foods , by Region USD Million (2025-2030)
  • Table 259. Human Micobiome Medical Foods , by Region USD Million (2025-2030)
  • Table 260. Human Micobiome Diagnostic Tests , by Region USD Million (2025-2030)
  • Table 261. Human Micobiome Drugs , by Region USD Million (2025-2030)
  • Table 262. Human Micobiome Others , by Region USD Million (2025-2030)
  • Table 263. Human Micobiome: by Application(USD Million)
  • Table 264. Human Micobiome Therapeutics , by Region USD Million (2025-2030)
  • Table 265. Human Micobiome Diagnostics , by Region USD Million (2025-2030)
  • Table 266. Human Micobiome Others , by Region USD Million (2025-2030)
  • Table 267. South America Human Micobiome, by Country USD Million (2025-2030)
  • Table 268. South America Human Micobiome, by Type USD Million (2025-2030)
  • Table 269. South America Human Micobiome, by Application USD Million (2025-2030)
  • Table 270. South America Human Micobiome, by Technology USD Million (2025-2030)
  • Table 271. South America Human Micobiome, by Disease USD Million (2025-2030)
  • Table 272. Brazil Human Micobiome, by Type USD Million (2025-2030)
  • Table 273. Brazil Human Micobiome, by Application USD Million (2025-2030)
  • Table 274. Brazil Human Micobiome, by Technology USD Million (2025-2030)
  • Table 275. Brazil Human Micobiome, by Disease USD Million (2025-2030)
  • Table 276. Argentina Human Micobiome, by Type USD Million (2025-2030)
  • Table 277. Argentina Human Micobiome, by Application USD Million (2025-2030)
  • Table 278. Argentina Human Micobiome, by Technology USD Million (2025-2030)
  • Table 279. Argentina Human Micobiome, by Disease USD Million (2025-2030)
  • Table 280. Rest of South America Human Micobiome, by Type USD Million (2025-2030)
  • Table 281. Rest of South America Human Micobiome, by Application USD Million (2025-2030)
  • Table 282. Rest of South America Human Micobiome, by Technology USD Million (2025-2030)
  • Table 283. Rest of South America Human Micobiome, by Disease USD Million (2025-2030)
  • Table 284. Asia Pacific Human Micobiome, by Country USD Million (2025-2030)
  • Table 285. Asia Pacific Human Micobiome, by Type USD Million (2025-2030)
  • Table 286. Asia Pacific Human Micobiome, by Application USD Million (2025-2030)
  • Table 287. Asia Pacific Human Micobiome, by Technology USD Million (2025-2030)
  • Table 288. Asia Pacific Human Micobiome, by Disease USD Million (2025-2030)
  • Table 289. China Human Micobiome, by Type USD Million (2025-2030)
  • Table 290. China Human Micobiome, by Application USD Million (2025-2030)
  • Table 291. China Human Micobiome, by Technology USD Million (2025-2030)
  • Table 292. China Human Micobiome, by Disease USD Million (2025-2030)
  • Table 293. Japan Human Micobiome, by Type USD Million (2025-2030)
  • Table 294. Japan Human Micobiome, by Application USD Million (2025-2030)
  • Table 295. Japan Human Micobiome, by Technology USD Million (2025-2030)
  • Table 296. Japan Human Micobiome, by Disease USD Million (2025-2030)
  • Table 297. India Human Micobiome, by Type USD Million (2025-2030)
  • Table 298. India Human Micobiome, by Application USD Million (2025-2030)
  • Table 299. India Human Micobiome, by Technology USD Million (2025-2030)
  • Table 300. India Human Micobiome, by Disease USD Million (2025-2030)
  • Table 301. South Korea Human Micobiome, by Type USD Million (2025-2030)
  • Table 302. South Korea Human Micobiome, by Application USD Million (2025-2030)
  • Table 303. South Korea Human Micobiome, by Technology USD Million (2025-2030)
  • Table 304. South Korea Human Micobiome, by Disease USD Million (2025-2030)
  • Table 305. Taiwan Human Micobiome, by Type USD Million (2025-2030)
  • Table 306. Taiwan Human Micobiome, by Application USD Million (2025-2030)
  • Table 307. Taiwan Human Micobiome, by Technology USD Million (2025-2030)
  • Table 308. Taiwan Human Micobiome, by Disease USD Million (2025-2030)
  • Table 309. Australia Human Micobiome, by Type USD Million (2025-2030)
  • Table 310. Australia Human Micobiome, by Application USD Million (2025-2030)
  • Table 311. Australia Human Micobiome, by Technology USD Million (2025-2030)
  • Table 312. Australia Human Micobiome, by Disease USD Million (2025-2030)
  • Table 313. Rest of Asia-Pacific Human Micobiome, by Type USD Million (2025-2030)
  • Table 314. Rest of Asia-Pacific Human Micobiome, by Application USD Million (2025-2030)
  • Table 315. Rest of Asia-Pacific Human Micobiome, by Technology USD Million (2025-2030)
  • Table 316. Rest of Asia-Pacific Human Micobiome, by Disease USD Million (2025-2030)
  • Table 317. Europe Human Micobiome, by Country USD Million (2025-2030)
  • Table 318. Europe Human Micobiome, by Type USD Million (2025-2030)
  • Table 319. Europe Human Micobiome, by Application USD Million (2025-2030)
  • Table 320. Europe Human Micobiome, by Technology USD Million (2025-2030)
  • Table 321. Europe Human Micobiome, by Disease USD Million (2025-2030)
  • Table 322. Germany Human Micobiome, by Type USD Million (2025-2030)
  • Table 323. Germany Human Micobiome, by Application USD Million (2025-2030)
  • Table 324. Germany Human Micobiome, by Technology USD Million (2025-2030)
  • Table 325. Germany Human Micobiome, by Disease USD Million (2025-2030)
  • Table 326. France Human Micobiome, by Type USD Million (2025-2030)
  • Table 327. France Human Micobiome, by Application USD Million (2025-2030)
  • Table 328. France Human Micobiome, by Technology USD Million (2025-2030)
  • Table 329. France Human Micobiome, by Disease USD Million (2025-2030)
  • Table 330. Italy Human Micobiome, by Type USD Million (2025-2030)
  • Table 331. Italy Human Micobiome, by Application USD Million (2025-2030)
  • Table 332. Italy Human Micobiome, by Technology USD Million (2025-2030)
  • Table 333. Italy Human Micobiome, by Disease USD Million (2025-2030)
  • Table 334. United Kingdom Human Micobiome, by Type USD Million (2025-2030)
  • Table 335. United Kingdom Human Micobiome, by Application USD Million (2025-2030)
  • Table 336. United Kingdom Human Micobiome, by Technology USD Million (2025-2030)
  • Table 337. United Kingdom Human Micobiome, by Disease USD Million (2025-2030)
  • Table 338. Netherlands Human Micobiome, by Type USD Million (2025-2030)
  • Table 339. Netherlands Human Micobiome, by Application USD Million (2025-2030)
  • Table 340. Netherlands Human Micobiome, by Technology USD Million (2025-2030)
  • Table 341. Netherlands Human Micobiome, by Disease USD Million (2025-2030)
  • Table 342. Rest of Europe Human Micobiome, by Type USD Million (2025-2030)
  • Table 343. Rest of Europe Human Micobiome, by Application USD Million (2025-2030)
  • Table 344. Rest of Europe Human Micobiome, by Technology USD Million (2025-2030)
  • Table 345. Rest of Europe Human Micobiome, by Disease USD Million (2025-2030)
  • Table 346. MEA Human Micobiome, by Country USD Million (2025-2030)
  • Table 347. MEA Human Micobiome, by Type USD Million (2025-2030)
  • Table 348. MEA Human Micobiome, by Application USD Million (2025-2030)
  • Table 349. MEA Human Micobiome, by Technology USD Million (2025-2030)
  • Table 350. MEA Human Micobiome, by Disease USD Million (2025-2030)
  • Table 351. Middle East Human Micobiome, by Type USD Million (2025-2030)
  • Table 352. Middle East Human Micobiome, by Application USD Million (2025-2030)
  • Table 353. Middle East Human Micobiome, by Technology USD Million (2025-2030)
  • Table 354. Middle East Human Micobiome, by Disease USD Million (2025-2030)
  • Table 355. Africa Human Micobiome, by Type USD Million (2025-2030)
  • Table 356. Africa Human Micobiome, by Application USD Million (2025-2030)
  • Table 357. Africa Human Micobiome, by Technology USD Million (2025-2030)
  • Table 358. Africa Human Micobiome, by Disease USD Million (2025-2030)
  • Table 359. North America Human Micobiome, by Country USD Million (2025-2030)
  • Table 360. North America Human Micobiome, by Type USD Million (2025-2030)
  • Table 361. North America Human Micobiome, by Application USD Million (2025-2030)
  • Table 362. North America Human Micobiome, by Technology USD Million (2025-2030)
  • Table 363. North America Human Micobiome, by Disease USD Million (2025-2030)
  • Table 364. United States Human Micobiome, by Type USD Million (2025-2030)
  • Table 365. United States Human Micobiome, by Application USD Million (2025-2030)
  • Table 366. United States Human Micobiome, by Technology USD Million (2025-2030)
  • Table 367. United States Human Micobiome, by Disease USD Million (2025-2030)
  • Table 368. Canada Human Micobiome, by Type USD Million (2025-2030)
  • Table 369. Canada Human Micobiome, by Application USD Million (2025-2030)
  • Table 370. Canada Human Micobiome, by Technology USD Million (2025-2030)
  • Table 371. Canada Human Micobiome, by Disease USD Million (2025-2030)
  • Table 372. Mexico Human Micobiome, by Type USD Million (2025-2030)
  • Table 373. Mexico Human Micobiome, by Application USD Million (2025-2030)
  • Table 374. Mexico Human Micobiome, by Technology USD Million (2025-2030)
  • Table 375. Mexico Human Micobiome, by Disease USD Million (2025-2030)
  • Table 376. Human Micobiome Sales: by Type(K Units)
  • Table 377. Human Micobiome Sales Probiotics , by Region K Units (2025-2030)
  • Table 378. Human Micobiome Sales Prebiotics , by Region K Units (2025-2030)
  • Table 379. Human Micobiome Sales Foods , by Region K Units (2025-2030)
  • Table 380. Human Micobiome Sales Medical Foods , by Region K Units (2025-2030)
  • Table 381. Human Micobiome Sales Diagnostic Tests , by Region K Units (2025-2030)
  • Table 382. Human Micobiome Sales Drugs , by Region K Units (2025-2030)
  • Table 383. Human Micobiome Sales Others , by Region K Units (2025-2030)
  • Table 384. Human Micobiome Sales: by Application(K Units)
  • Table 385. Human Micobiome Sales Therapeutics , by Region K Units (2025-2030)
  • Table 386. Human Micobiome Sales Diagnostics , by Region K Units (2025-2030)
  • Table 387. Human Micobiome Sales Others , by Region K Units (2025-2030)
  • Table 388. South America Human Micobiome Sales, by Country K Units (2025-2030)
  • Table 389. South America Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 390. South America Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 391. South America Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 392. South America Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 393. Brazil Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 394. Brazil Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 395. Brazil Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 396. Brazil Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 397. Argentina Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 398. Argentina Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 399. Argentina Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 400. Argentina Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 401. Rest of South America Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 402. Rest of South America Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 403. Rest of South America Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 404. Rest of South America Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 405. Asia Pacific Human Micobiome Sales, by Country K Units (2025-2030)
  • Table 406. Asia Pacific Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 407. Asia Pacific Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 408. Asia Pacific Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 409. Asia Pacific Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 410. China Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 411. China Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 412. China Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 413. China Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 414. Japan Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 415. Japan Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 416. Japan Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 417. Japan Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 418. India Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 419. India Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 420. India Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 421. India Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 422. South Korea Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 423. South Korea Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 424. South Korea Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 425. South Korea Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 426. Taiwan Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 427. Taiwan Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 428. Taiwan Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 429. Taiwan Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 430. Australia Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 431. Australia Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 432. Australia Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 433. Australia Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 434. Rest of Asia-Pacific Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 435. Rest of Asia-Pacific Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 436. Rest of Asia-Pacific Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 437. Rest of Asia-Pacific Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 438. Europe Human Micobiome Sales, by Country K Units (2025-2030)
  • Table 439. Europe Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 440. Europe Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 441. Europe Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 442. Europe Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 443. Germany Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 444. Germany Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 445. Germany Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 446. Germany Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 447. France Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 448. France Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 449. France Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 450. France Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 451. Italy Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 452. Italy Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 453. Italy Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 454. Italy Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 455. United Kingdom Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 456. United Kingdom Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 457. United Kingdom Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 458. United Kingdom Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 459. Netherlands Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 460. Netherlands Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 461. Netherlands Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 462. Netherlands Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 463. Rest of Europe Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 464. Rest of Europe Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 465. Rest of Europe Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 466. Rest of Europe Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 467. MEA Human Micobiome Sales, by Country K Units (2025-2030)
  • Table 468. MEA Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 469. MEA Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 470. MEA Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 471. MEA Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 472. Middle East Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 473. Middle East Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 474. Middle East Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 475. Middle East Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 476. Africa Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 477. Africa Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 478. Africa Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 479. Africa Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 480. North America Human Micobiome Sales, by Country K Units (2025-2030)
  • Table 481. North America Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 482. North America Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 483. North America Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 484. North America Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 485. United States Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 486. United States Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 487. United States Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 488. United States Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 489. Canada Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 490. Canada Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 491. Canada Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 492. Canada Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 493. Mexico Human Micobiome Sales, by Type K Units (2025-2030)
  • Table 494. Mexico Human Micobiome Sales, by Application K Units (2025-2030)
  • Table 495. Mexico Human Micobiome Sales, by Technology K Units (2025-2030)
  • Table 496. Mexico Human Micobiome Sales, by Disease K Units (2025-2030)
  • Table 497. Human Micobiome: by Type(USD/Units)
  • Table 498. Research Programs/Design for This Report
  • Table 499. Key Data Information from Secondary Sources
  • Table 500. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Micobiome: by Type USD Million (2018-2023)
  • Figure 5. Global Human Micobiome: by Application USD Million (2018-2023)
  • Figure 6. South America Human Micobiome Share (%), by Country
  • Figure 7. Asia Pacific Human Micobiome Share (%), by Country
  • Figure 8. Europe Human Micobiome Share (%), by Country
  • Figure 9. MEA Human Micobiome Share (%), by Country
  • Figure 10. North America Human Micobiome Share (%), by Country
  • Figure 11. Global Human Micobiome: by Type K Units (2018-2023)
  • Figure 12. Global Human Micobiome: by Application K Units (2018-2023)
  • Figure 13. South America Human Micobiome Share (%), by Country
  • Figure 14. Asia Pacific Human Micobiome Share (%), by Country
  • Figure 15. Europe Human Micobiome Share (%), by Country
  • Figure 16. MEA Human Micobiome Share (%), by Country
  • Figure 17. North America Human Micobiome Share (%), by Country
  • Figure 18. Global Human Micobiome: by Type USD/Units (2018-2023)
  • Figure 19. Global Human Micobiome share by Players 2023 (%)
  • Figure 20. Global Human Micobiome share by Players (Top 3) 2023(%)
  • Figure 21. Global Human Micobiome share by Players (Top 5) 2023(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. 4D Pharma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. 4D Pharma (United Kingdom) Revenue: by Geography 2023
  • Figure 25. Yakult Honsha Co., Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Yakult Honsha Co., Ltd (Japan) Revenue: by Geography 2023
  • Figure 27. DuPont (United States) Revenue, Net Income and Gross profit
  • Figure 28. DuPont (United States) Revenue: by Geography 2023
  • Figure 29. Rebiotix, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Rebiotix, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Metabiomics Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Metabiomics Corporation (United States) Revenue: by Geography 2023
  • Figure 33. Second Genome Inc (United States) Revenue, Net Income and Gross profit
  • Figure 34. Second Genome Inc (United States) Revenue: by Geography 2023
  • Figure 35. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 37. Merck & Co., Inc (United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck & Co., Inc (United States) Revenue: by Geography 2023
  • Figure 39. Synthetic Biologics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Synthetic Biologics, Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Seres Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 42. Seres Therapeutics (United States) Revenue: by Geography 2023
  • Figure 43. Microbiome Therapeutics LLC (United States) Revenue, Net Income and Gross profit
  • Figure 44. Microbiome Therapeutics LLC (United States) Revenue: by Geography 2023
  • Figure 45. Global Human Micobiome: by Type USD Million (2025-2030)
  • Figure 46. Global Human Micobiome: by Application USD Million (2025-2030)
  • Figure 47. South America Human Micobiome Share (%), by Country
  • Figure 48. Asia Pacific Human Micobiome Share (%), by Country
  • Figure 49. Europe Human Micobiome Share (%), by Country
  • Figure 50. MEA Human Micobiome Share (%), by Country
  • Figure 51. North America Human Micobiome Share (%), by Country
  • Figure 52. Global Human Micobiome: by Type K Units (2025-2030)
  • Figure 53. Global Human Micobiome: by Application K Units (2025-2030)
  • Figure 54. South America Human Micobiome Share (%), by Country
  • Figure 55. Asia Pacific Human Micobiome Share (%), by Country
  • Figure 56. Europe Human Micobiome Share (%), by Country
  • Figure 57. MEA Human Micobiome Share (%), by Country
  • Figure 58. North America Human Micobiome Share (%), by Country
  • Figure 59. Global Human Micobiome: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • 4D Pharma (United Kingdom)
  • Yakult Honsha Co., Ltd (Japan)
  • DuPont (United States)
  • Rebiotix, Inc. (United States)
  • Metabiomics Corporation (United States)
  • Second Genome Inc (United States)
  • AstraZeneca (United Kingdom)
  • Merck & Co., Inc (United States)
  • Synthetic Biologics, Inc. (United States)
  • Seres Therapeutics (United States)
  • Microbiome Therapeutics LLC (United States)
Additional players considered in the study are as follows:
Vedanta BioSciences (United States) , Seres Therapeutics (United States) , Enterome Bioscience (France) , Seres Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 178 Pages 70 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Micobiome Quantitative research analysis
Global Human Micobiome Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as 4D Pharma (United Kingdom), Yakult Honsha Co., Ltd (Japan), DuPont (United States), Rebiotix, Inc. (United States), Metabiomics Corporation (United States), Second Genome Inc (United States), AstraZeneca (United Kingdom), Merck & Co., Inc (United States), Synthetic Biologics, Inc. (United States), Seres Therapeutics (United States) and Microbiome Therapeutics LLC (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Therapeutic Applications Expected to Hold the Highest Share During Forecast Period" is seen as one of major influencing trends for Human Micobiome Market during projected period 2023-2030.
The Human Micobiome market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates Human Micobiome Market to reach USD3026.0 Million by 2030.

Know More About Global Human Micobiome Report?

Have a Query? Click Here

Other Related Reports

Avanafil Comprehensive Study by Application (Young Age Patients, Old Age Patients), Forms (50 Mg Avanafil, 100 Mg Avanafil, 200 Mg Avanafil), Therapeutic Areas (Musculoskeletal, Nephrology, Rheumatol...
$ 3450
Medical Footwear Comprehensive Study by Type (Shoes & Boots, Sandals, Others {Slippers, Flip-flops, Insoles}), Application (Diabetic Shoes, Arthritis Shoes, Bunions & Hallux Valgus Shoes, Flat Feet S...
$ 3750
Benzocaine Comprehensive Study by Application (Cosmetics, Anesthetic, Others), Form (Spray, Gel, Ointment, Paste), Purity (98%, 99%) Players and Region - Global Market Outlook to 2030
$ 3500
Cleanroom Consumables Comprehensive Study by Type (Safety Consumables {Frocks, Boot Covers, Shoe Covers, Bouffants, Pants & Face Masks, Other}, Cleaning Consumables {Mops, Buckets, Wringers, Squeegee...
$ 3750
Surgical Mask Comprehensive Study by Type (Basic Surgical Mask, Anti-Fog Surgical Mask, Fluid/Splash Resistant Surgical Mask, N95 Mask, Others), Application (Individual, Health Professionals, Industr...
$ 3650
Iron Supplement Comprehensive Study by Type (Tablet, Liquid), Application (Kids, Adult), End users (Food Industry, Pharmaceutical Industry, Chemical Industry), Form (Ferrous and Ferric iron salts (Fe...
$ 3650